There are 700 resources available
489P - SDF-1alpha, SCF, and eotaxin are prognostic serum biomarkers in gastric cancer
Presenter: Jefim Brodkin
Session: Poster Display session
490P - Activating EGFR/HER3-induced epithelial-mesenchymal transition by ESM1 promotes gastric cancer progression via modulating interplay between Akt and angiopoietin-2 signaling
Presenter: Yi-Chieh Yang
Session: Poster Display session
491P - Novel DNA methylation markers for early detection of esophageal squamous cell carcinoma and cardia gastric adenocarcinoma
Presenter: Zhiyuan Fan
Session: Poster Display session
492TiP - HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2-positive esophageal squamous cell carcinoma patients
Presenter: Kristian Egebjerg
Session: Poster Display session
493TiP - A phase II study of mFOLFOX6 plus nivolumab as initial therapy for patients with advanced esophageal squamous-cell cancer: FLONTALE trial
Presenter: YOHEI KUBOTA
Session: Poster Display session
494TiP - Efficacy and safety of cadonilimab and COX-2 inhibitor combined with oxaliplatin and capecitabine (XELOX) in perioperative treatment for locally advanced resectable gastric adenocarcinoma: A prospective, single-center, randomized, phase II trial
Presenter: Yan Qian
Session: Poster Display session
495TiP - CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)
Presenter: Kohei Shitara
Session: Poster Display session
496TiP - Randomised phase II study evaluating trifluridine/tipiracil (FTD/TPI) plus oxaliplatin ± nivolumab versus FOLFOX ± nivolumab in patients with HER2-negative locally advanced, recurrent or metastatic gastric, oesophageal or junctional adenocarcinoma (aGA/GE
Presenter: Christelle de la Fouchardiere
Session: Poster Display session
497TiP - Randomized phase II trial of trifluridine/tipiracil plus ramucirumab versus trifluridine/tipiracil for pre-treated patients with advanced gastric or gastroesophageal junction adenocarcinoma (RETRIEVE study, WJOG15822G)
Presenter: Naoki Takahashi
Session: Poster Display session
498TiP - Adjuvant trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surg
Presenter: Vincenzo Nasca
Session: Poster Display session